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Abstract Familial (FAD) and sporadic (SAD) Alzheimer’s
disease do not share all pathomechanisms, but knowledge on
their molecular differences is limited. We previously reported
that cell cycle control distinguishes lymphocytes from SAD
and FAD patients. Significant differences were found in p21
levels of SAD compared to FAD lymphocytes. Since p21 can
also regulate apoptosis, the aim of this study was to compare
the response of FAD and SAD lymphocytes to oxidative stress
like 2-deoxy-D-ribose (2dRib) treatment and to investigate the
role of p21 levels in this response. We report that FAD cells
bearing seven different PS1 mutations are more resistant to
2dRib-induced cell death than control or SAD cells: FAD cells
showed a lower apoptosis rate and a lower depolarization of
the mitochondrial membrane. Despite that basal p21 cellular
content was lower in FAD than in SAD cells, in response to
2dRib, p21 mRNA and protein levels significantly increased
in FAD cells. Moreover, we found a higher cytosolic accumu-
lation of p21 in FAD cells. The transcriptional activation of
p21 was shown to be dependent on p53, as it can be blocked
by PFT-α, and correlated with the increased phosphorylation
of p53 at Serine 15. Our results suggest that in FAD lympho-
cytes, the p53-mediated increase in p21 transcription, together
with a shift in the nucleocytoplasmic localization of p21, con-
fers a survival advantage against 2dRib-induced apoptosis.
This compensatory mechanism is absent in SAD cells. Thus,
therapeutic and diagnostic designs should take into account pos-
sible differential apoptotic responses in SAD versus FAD cells.
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Background
Alzheimer’s disease (AD) is a neurodegenerative disorder and
the most common age-related dementia worldwide which has
become one of the key unmet medical needs of modern
civilization.
AD is clinically and neuropathologically heterogeneous,
but two main forms of the disease are described: familial
Alzheimer’s disease (FAD), which accounts for approximate-
ly 1 % of all affected individuals, and sporadic Alzheimer’s
disease (SAD) [1, 2]. FAD has an early onset, before the age of
65 years, and in most cases has a genetic basis—a missense
mutation in one of the three genes encoding transmembrane
proteins involved in the amyloidogenic pathway: amyloid β
precursor protein (AβPP), presenilin 1 (PS1), and presenilin 2
(PS2). Both sporadic and familial AD forms share main neu-
ropathological characteristics, namely β-amyloid plaques,
neurofibrillary tangles, and regionalized neuronal loss.
However, our understanding of the role that these features of
AD play in the etiology of these two forms of the disease
remains incomplete and is disputed [3]. The possibility of
distinguishing FAD from SAD is of fundamental relevance
for the identification of future disease markers, novel drug
targets, and therapeutic strategies toward AD. Currently, a
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very limited number of experimental studies have directly
compared FAD and SAD mechanisms.
Most FAD mutations occur in PS1; so far over 227 have
been identified in PS1 emphasizing a key role of PS1 in FAD
pathogenesis [4]. PS1 is a 48-kDa protein which sustains en-
zymatic core of the γ-secretase complex responsible for the
generation of toxic Aβ from AβPP [5, 6]. These findings
strongly support the amyloid cascade hypothesis in the path-
ogenesis of AD [7, 8]. Nevertheless, recent data indicate dif-
ferences in SAD and FAD pathogenesis; SAD and FAD pres-
ent different clinicopathological features [9]. Moreover, in the
context of the so-called Bcell cycle hypothesis^, we previously
reported that peripheral cells from either FAD or SAD patients
exhibited distinct cell cycle alterations [10]. These cell cycle
disturbances are considered to be systemic manifestations of
the proposed aberrant cell cycle activation in differentiated
neurons in AD [11–13]. In particular, we reported that SAD
compared to FAD B-lymphocytes showed differences in the
expression profiles of 90 cell cycle-related genes, and a
marked increase in the level of the p21/CIP1/WAF1 protein,
which promotes G1-arrest [10]. p21 is a cyclin-dependent
kinase inhibitor, which inhibits cell cycle progression [14,
15]. However, p21 has been shown to play additional roles
depending on cell status as well as its subcellular distribution
[14, 16–18]. Notably, p21 can function as a modulator of
apoptosis [18–21]. On these grounds, we hypothesized that
differences in p21 levels between SAD and FAD lymphocytes
could play a role in the cellular response to 2-deoxy-D-ribose
(2dRib) that induces apoptosis via a mechanism that involves
oxidative stress [22]. Thus, the aim of this study was to com-
pare the apoptotic response of FAD and SAD lymphocytes to
2dRib, and to investigate the role of p21 levels in this
response.
Results
Higher Survival and Lower Apoptotic Response of FAD
Lymphocytes Compared to SAD and Control Cells
To determine the dose-response effects of 2dRib, lymphocytes
from familial (FAD) and sporadic (SAD) Alzheimer’s pa-
tients, as well as age-matched controls were incubated in the
absence or in the presence of escalating concentrations (10–
50 mM) of 2dRib, and cell viability was determined by MTT
assay. As shown in Fig. 1a, 2dRib decreased cell viability in a
dose-dependent manner. Further experiments were carried out
at 30-mM concentration of 2dRib. Figure 1b shows a signifi-
cant resistance to 2dRib-induced cell death of lymphocytes from
FAD patients, compared to either age-matched controls or lym-
phocytes from SAD patients. Moreover, no differences were
detected between lymphocytes from younger control individuals
(FAD ctr) or older (SAD ctr) patients (Fig. 1b), showing that
sensitivity to 2dRib is not age-dependent.
Data in Fig. 1c demonstrates that the differences in cell
survival between SAD and FAD cells upon 2dRib treatment
were reflected in the apoptotic levels measured by flow cyto-
metric analysis of the phosphatidylserine exposure using
Annexin V-FITC and Propidium Iodide (PI). The analysis
revealed the lower apoptotic response of FAD lymphocytes
to 2dRib, compared to SAD cells and both control groups. In
addition, it is shown that while SAD cells are more vulnerable
to apoptosis than age-matched control cells, the opposite oc-
curs with FAD lymphocytes—they are more resistant to
2dRib-induced apoptosis than their respective control
(Fig. 1c).
We sought to further determine the molecular mecha-
nism involved in the apoptotic cell response to 2dRib.
Considering that the intrinsic apoptotic pathway is charac-
terized by several morphological and biochemical features
that involve mitochondrial membrane depolarization at the
early apoptosis stage and lead in the executor stage to
nuclear DNA fragmentation, the 2dRib-induced apoptotic
response was next assessed by flow cytometry analysis of
mitochondrial membrane potential and cellular DNA
content.
For determining whether the response to 2dRib treat-
ment corresponds to the disruption of active mitochon-
dria, we employed the membrane-permeant JC-1 dye,
used in apoptosis studies to monitor alterations in mito-
chondrial membrane potential (MMP) [23, 24]. At high
MMP, JC-1 forms aggregates in mitochondria yielding a
red colored emission, while at low MMP, the JC-1 dye
is predominantly a monomer that yields green fluores-
cence. Consequently, mitochondria depolarization is in-
dicated by a change in JC-1 fluorescence from red to
green and by a decrease in the red/green fluorescence
intensity ratio. As shown in Fig. 2a, b, after 2dRib
treatment lymphocytes from SAD patients showed a
much higher increase in the percentage of cells with
depolarized mitochondrial membranes and a significant-
ly lower mean red/green fluorescence ratio, compared
both to age-matched control cells and FAD cells. In
contrast, FAD cells demonstrated an increased resistance
to mitochondrial membrane depolarization, in agreement
with lower apoptosis and a higher survival of FAD cells
shown in Fig. 1. Thus, 2dRib strongly induces intrinsic
apoptotic pathways involving mitochondria in SAD
cells, but FAD cells exhibit protection.
Figure 3a shows a representative experiment of cell cy-
cle status before and after treatment with 2dRib, while
Fig. 2b below shows the percentage of cells in subG1
containing hypodiploid nuclei in lymphocytes from controls
and AD patients. As demonstrated in Fig. 3a, b, upon
2dRib SAD cells showed a higher accumulation of
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hypodiploid nuclei compared to cells of age-matched con-
trols and FAD patients, in consistency with results shown
in Figs. 1 and 2.
Figure 3c demonstrates, for comparative purposes, the
effect of 2dRib treatment in freshly isolated B-
lymphocytes from control and SAD subjects. It is notewor-
thy that a higher than in controls percentage of cells in
subG1 after the 2dRib addition in SAD lymphocytes fresh-
ly isolated from patients’ blood corresponds to the same
result in SAD immortalized lymphocytes (Fig. 3c). This
data is in agreement with previous reports indicating that
the cellular response of lymphocytes from AD patients is
not affected by the viral transformation [25, 26].
Altogether, this data indicated that SAD lymphocytes
are more vulnerable to apoptosis evoked by redox stress
induced by 2dRib, than cells from FAD patients, and con-
trols age-matched to SAD and FAD subjects. In addition,
our results suggest activation of the intrinsic mitochondrial
activated pathway by 2dRib in SAD cells resulting in
DNA fragmentation and the resistance of FAD cells to
2dRib-induced mitochondrial membrane depolarization
and intrinsic apoptosis.
Molecular Mechanism Protecting FAD Cells
from 2dRib-Induced Apoptosis
Increased Protein and mRNA Levels of p21 in FAD Cells
after 2dRib Treatment
We previously reported significant differences in p21 basal
levels in SAD lymphocytes compared to cells from control
or FAD individuals. Since it is known that p21, besides con-
trolling the G1/S checkpoint, can regulate apoptosis [27, 28],
we were interested in studying whether p21 levels play a role
in the cellular response of AD cells to 2dRib treatment. The
mRNA and protein p21 levels in SAD and FAD cells com-
pared to age-matched control cells are shown in Fig. 4. In
agreement with our previous work [10], we detected higher
basal levels of the 21 protein in lymphocytes from SAD cells
compared to either cells from FAD or control individuals
(Fig. 4b). It was considered that the increase in p21 levels
promoted G1 arrest, and therefore SAD cells showed a
prolonged G1 phase [10]. Interestingly, the basal levels of
p21 mRNA levels in SAD cells did not increase (Fig. 4a),
suggesting that the increased basal p21 levels in SAD cells
Fig. 1 Survival and apoptosis rates of FAD and SAD lymphocytes
treated with 2dRib. Lymphocytes from eight SAD patients, eight
control individuals age-matched to SAD subjects, seven FAD patients,
and eight control individuals age-matched to FAD subjects were ana-
lyzed. a Cell survival rates measured by MTTassay after seeding of cells
at initial density of 1 × 106 ×mL−1 and incubation for 24 h in the presence
of 10, 20, 30, 40, and 50 mM 2dRib. b Cell survival rates measured by
MTT assay after seeding of cells at initial density of 1 × 106 × mL−1 and
incubation for 24 h with 30 mM 2dRib. These conditions were used in all
further experiments with 2dRib. c Apoptosis levels assessed by flow
cytometry using Annexin V-FITC and PI in cells incubated for 24 h in
the presence of 30 mM 2dRib. Increase in the percentage of apoptotic
cells was calculated as percent of cells Annexin V positive after 2dRib
stimulation minus percent of Annexin V positive cells without stimula-
tion. Data shown are the means ± standard errors of the means (SEM)
calculated using the Mann–Whitney test for at least three independent
experiments carried out in each cell line derived from the study subjects.
Statistically significant differences are marked: p < 0.001, **p < 0.01,
*p < 0.05
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result from a deficient degradation of the p21 protein in the
proteasome.
Despite the fact that FAD cells show a lower basal p21
cellular content than SAD cells, particularly high increases
in p21 mRNA and protein levels occurred in FAD cells in
response to 2dRib (Fig. 4).
Intracellular Localization of p21. Increased p21 Protein
Levels in Cytoplasm of FAD Cells After Apoptotic Stimulation
p21 has been considered a protein showing different nuclear
versus cytosolic functions [29, 30]. Therefore, we decided to
examine whether there are differences in the subcellular
Fig. 2 Mitochondrial membrane potential in SAD and FAD lymphocytes
treated with 2dRib. Lymphocytes from eight SAD patients, eight control
individuals age-matched to SAD subjects, seven FAD patients, and eight
control subjects age-matched to FAD subjects were incubated for 24 h in
the absence or in the presence of 30 mM 2dRib. After 24 h, cells were
stained with cationic dye JC-1 and analyzed by flow cytometry. a
Representative dot plots showing percentage of cells with high and low
MMP in the absence or in the presence of 2dRib. b Summary plot show-
ingmean ratios of the percentages of cells with highMMP/lowMMP. For
each cell line, means ± SEM were calculated based on at least three
independent experiments using Mann–Whitney test. Statistically signifi-
cant differences are marked: ***p < 0.001; **p < 0.01; *p < 0.05
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localization of p21 in control, SAD, and FAD lymphocytes
under basal conditions and after 2dRib stimulation. For this
purpose, cells were immunostained with an anti-p21 antibody
and processed for confocal laser imaging. In addition, we
performed cell fractionation and analyzed the protein extracts
by immunoblotting. Figure 5a shows marked differences in
the subcellular distribution of p21 between SAD and FAD
cells under basal conditions. It demonstrates that p21 is locat-
ed preferentially in the nucleus of FAD and control cells, while
it appears that in SAD cells it is distributed prevailingly in the
cytoplasm. Similar results were obtained by immunoblotting,
as shown in Fig. 5c.
After 2dRib treatment, the analysis of p21 subcellular dis-
tribution, either by confocal microscopy (Fig. 5b) or by im-
munoblotting (Fig. 5c) revealed an opposite response to 2dRib
in SAD cells compared to control and FAD cells. Cytosolic
p21 levels increased in control and most significantly in FAD
cells, while they decreased in SAD cells (Fig. 5b, c). In
Fig. 5b, DAPI images after treatment with 30 mM 2dRib
depict fragmented, apoptotic nuclei in SAD and control cells.
In contrast, in FAD cells nuclei are without such signs, which
is associated with a predominantly cytosolic localization of
p21 and a higher level of p21 than in SAD and control cells.
p53-Dependent Transcriptional Regulation of p21 in FAD
Cells
As transcriptional activation of the p21 gene can occur
through p53-dependent and p53-independent mechanisms,
we first tested whether transcriptional activation of the p21
gene was dependent on p53 activity. For this purpose, we
determined by immunoblotting the phosphorylation of
p53 at Ser 15, together with total p53 and p21 levels in the
absence and in the presence of the p53 inhibitor PFT-α [31],
(Fig. 6), and analyzed the influence of this inhibitor on cell
survival after 2dRib treatment (Fig. 7).
Fig. 3 Hypodiploid nuclei
content in SAD and FAD
lymphocytes treated with 2dRib.
Lymphocytes from eight SAD
patients, eight control individuals
age-matched to SAD subjects,
seven FAD patients, and eight
control individuals age-matched
to FAD subjects were incubated
for 24 h in the absence or in the
presence of 30 mM 2dRib,
permeabilized and stained with PI
and analyzed by flow cytometry.
Data shown are the mean ± SEM
for at least three independent ex-
periments carried out for each of
the cell lines. a Representative
cytograms showing cell cycle
profiles based on PI staining.
SubG1 phase containing hypo-
diploid nuclei is marked. bMean
increases in SubG1 levels calcu-
lated as percentage of 2dRib
treated cells gated in SubG1 phase
minus percentage of untreated
cells gated in SubG1 phase. c
Mean increases in SubG1 levels
calculated as in b in B lympho-
cytes freshly isolated from SAD
patients and control subjects after
treatment with 10 mM 2dRib.
Statistically significant differ-
ences (Mann–Whitney test) are
marked: **p < 0.01; *p < 0.05
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As shown in Fig. 6a, the addition of 2dRib appears to
activate the p53 pathway in all cell types, as reflected by the
increase in the phosphorylated (active) form of the protein,
although total p53 levels rather decreased (Fig. 6b). The
highest increase in the level of the active p53 form occurred
in FAD cells, which corresponds to the highest increase in p21
level in FAD cells compared to control and SAD cells
(Fig. 6c). On the other hand, the addition of PFT-α effectively
decreased the 2dRib-induced increase in Ser15 p53 levels, and
reduced the cellular content of p21, while PFT-α alone did not
affect the basal levels of p53 and p21. Together, these results
suggest that 2dRib activates the transcription of p21 in all cell
types, but it seems that FAD cells exhibit an enhanced re-
sponse to the 2dRib-induced increase in p21 levels. Finally,
we assessed the effects of PFT-α on 2dRib-induced cell re-
sponses. PFT-α did not affect the survival of control or AD
cells, as assessed by the MTT assay in the absence of 2dRib
(not shown), but increased cell death induced by 2dRib in all
cell types (Fig. 7). Under these conditions, death of FAD lym-
phocytes is the same than that of control or SAD cells.
Altogether, this data suggests that the higher survival and low-
er apoptotic response to 2dRib in FAD lymphocytes compared
to SAD and control cells is determined by the highest activa-
tion of the p53-p21 pathway and the shift of the p21 localiza-
tion from the nucleus to the cytoplasm.
Discussion
This work was undertaken to study whether the reported
differences in p21 levels between lymphocytes from SAD
and FAD individuals carrying seven different PS1 muta-
tions (M139V, L153V, H163R, S170F, F177L, I213F,
E318G) [10], play a role in cell fate (survival/death) when
they are challenged by oxidative stress, like the one pro-
vided by the reducing sugar 2dRib [32, 33]. We report here
that peripheral B lymphocytes from SAD and FAD patients
differ in cellular response to this apoptotic stimulus. Cells
Fig. 4 p21 mRNA and protein levels in SAD and FAD lymphocytes
before and after 2dRib treatment. Lymphocytes from eight SAD
patients, eight SAD age-matched control subjects, five FAD patients,
and five FAD age-matched control subjects were incubated for 24 h in
the absence or in the presence of 30 mM 2dRib, and analyzed. a Relative
p21 messenger RNA (mRNA) abundance in lymphocytes. Isolated total
mRNAwas subjected to quantitative real-time polymerase chain reaction.
Relative p21 mRNA levels were normalized to β-actin expression, and
values for control cells were set as 1. b p21 protein levels in lymphocytes
were assessed with immunoblotting (representative immunoblots are
shown on top), and analyzed using densitometry (below); p21 protein
levels were quantified in relation to β-actin. All quantitative data repre-
sents the means ± SEM for at least three independent experiments carried
out for each cell line. Statistically significant differences (two-way
ANOVA test with Tukey post-test) are marked ***p < 0.001, *p < 0.05
Fig. 5 Subcellular localization of p21 in SAD and FAD lymphocytes
before and after 2dRib treatment. Subcellular localization of p21 was
assessed by confocal scanning microscopy (a) and (b), and by
immunoblotting (c). Lymphocytes were incubated for 24 h in the
absence (a) or in the presence (b) of 30 mM 2dRib. a, b Cells were
collected and stained with anti-p21 antibody followed by secondary an-
tibody labeled with Alexa Fluor 488. 4′,6-Diamidino-2-phenylindole
(DAPI) was used for nuclear staining. Confocal images are merged, mag-
nification ×63. Quantitative analysis of p21 cytosol/nucleus ratio was
obtained using ImageJ software. Shown are means ± SEM from repre-
sentative experiments in which at least 10 cells were analyzed
(**p < 0.01, ***p < 0.001; Mann–Whitney test). c Immunoblotting of
p21 protein in cytosolic fraction of lymphocytes from six SAD patients,
six control subjects age-matched to SAD patients, and from six FAD
patients. Representative immunoblots are shown on top, the densitomet-
ric quantitation of all immunoblots are shown below. Data represents the
means ± SEM for at least three independent experiments carried out for
each cell line. Statistically significant differences (two-way ANOVA test)
are marked ***p < 0.001, **p < 0.01, *p < 0.05
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from PS1 mutation carriers are more resistant to 2dRib-
induced cell death when compared with age-matched con-
trols or SAD patients. To the best of our knowledge, this is
the first report comparing the vulnerability of SAD and
FAD cells against acute oxidative stress.
Increasing evidence indicates that SAD and FAD patients
present distinct clinical and pathological features [9].
Moreover, several early pathogenic processes seem to differ-
entiate SAD from FAD, including different genetic and envi-
ronmental factors (reviewed in [34, 35]). For example, SAD
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risk genes identified by genome-wide association studies
comprise multiple loci associated with lipid metabolism, in-
nate immunity and cell signaling, but not APP, PS1, or PS2
[36, 37]. In addition, hundreds of recent clinical trials with
potential drugs targeting the amyloidogenic pathway have
failed. One of the postulated reasons is that these therapeutics
were based and tested in preclinical studies using FADmodels
that are not fully applicable to SAD. The identification of
molecular differences between SAD and FAD is thus impor-
tant for further drug development. In addition, there is an
urgent need for a blood biochemical test that can support the
early diagnosis of AD and all biological modalities involving
blood cells and plasma are explored for this aim [38]. From
this perspective, knowledge on possible SAD and FAD differ-
ences in phenotypes and protein profiles including these of
blood cells is of growing significance.
While this is the first comparison of stress response in
SAD and FAD cells, selective impairment of cell survival
mechanisms in peripheral cells derived from AD patients
was previously reported [39, 40], although there is some
controversy as to whether AD cells are more resistant or
more vulnerable to a number of cell stressors [41, 42].
2dRib is known to induce apoptosis mainly by depleting
reduced glutathione (GSH), the cellular thiol responsible for
Fig. 6 Effects of 2dRib and PFT-α on cellular levels of phospho-p53 (a),
total p53 (b), and p21 (c) in FAD and SAD lymphocytes. Cells from
seven SAD patients, seven control subjects and from FAD patients were
incubated for 24 h in the absence or in the presence of 30 mM 2dRib and/
or 30 μM PFT-α and analyzed by immunoblotting. Protein levels were
quantified by densitometry in relation toβ-actin and are shown below the
representative immunoblots. The densitometric data represents the
means ± SEM for at least three independent experiments carried out for
each cell line. Statistically significant differences (two-way ANOVA test
with Tukey post-test) are marked ***p < 0.001; **p < 0.01; *p < 0.05
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preserving reduced intracellular environment and blocking
the accumulation of reactive oxygen species (ROS) [32,
33]. The decrease of cellular GSH results in the ROS-
induced activation of mitochondrial apoptotic signaling
[43]. In our study, cell death induced by 2dRib treatment
showed in all SAD, FAD, and control lymphocytes charac-
teristics of intrinsic apoptosis involving mitochondrial path-
way, in agreement with the known cellular mechanism of
2dRib activity. However, we found a lower sensitivity of
FAD lymphocytes to 2dRib accompanied by a lower dissi-
pation of the mitochondrial membrane potential, and a de-
creased percentage of apoptotic cells compared to lympho-
cytes from SAD or control individuals.
In lymphocytes, the p53 tumor suppressor protein is a main
sensor of intrinsic stress stimuli such as oxidizing intracellular
environments [44]. The phosphorylation of p53 at Ser15 plays
a fundamental function in promoting p53 transcriptional ac-
tivity including the expression of p21, the key target of p53
(reviewed in [45]). In our study, 2dRib induced the phosphor-
ylation of p53 at Ser15 in all cell types; however, the level of
phosphorylated p53 in FAD cells was significantly higher than
in control or SAD cells, and correlated with the 3-fold increase
in p21 transcripts in FAD compared to control or SAD cells.
Thus, the magnitude of the p53-mediated activation of p21
gene transcription was strikingly greater in FAD cells. As
p21 is a key regulator of apoptosis (reviewed in [14, 16]), this
difference appears to account for the distinct apoptotic re-
sponse of FAD to 2dRib.
Interestingly, despite transcription activation, levels of the
p21 protein either decreased in SAD cells or did not change in
control lymphocytes. It is of note, and in accordance to our
previous reports [10], that SAD cells showed higher basal
levels of the p21 protein than FAD or control lymphocytes.
Taken together, these results suggest differences in the rates of
p21 transcription and degradation between control, SAD, and
FAD lymphocytes.
In addition to the increased transcriptional activation of the
p21 gene and the increased cellular content of p21 observed in
FAD lymphocytes after 2dRib treatment, we also found an
increase in the p21 cytosolic content of FAD cells. This result
explains the lower apoptotic response of FAD lymphocytes,
because p21 is associated with cell cycle arrest when present
in the nucleus, and with the apoptotic block when localized in
the cytoplasm (reviewed in [46, 47]). For example, cytoplas-
mic p21 has been reported to protect etoposide-induced apo-
ptosis in leukemia cells [28], and it is thought to be a positive
modulator of cell survival [30, 48].Moreover, cytoplasmically
localized p21 binds to and inhibits the activity of proteins
directly involved in the induction of apoptosis, including
procaspase 3, caspase 8, caspase 10, stress-activated protein
kinases (SAPKs) and apoptosis signal-regulating kinase 1
(ASK1) [18, 19, 49, 50].
Together, our results suggest that the increased activation
of p21 mRNA expression in a p53-dependent manner, togeth-
er with a preferential cytosolic localization of p21 and appar-
ently higher p21 protein stability, confers a survival advantage
to FAD lymphocytes compared with control or SAD cells.
Importantly, B lymphocytes contain high levels of PS1
[51]. Thus, our data suggest substantially altered functions
of mutPS1 versus wtPS1 in the oxidative stress response
which involves the activation of the p53–p21 signaling path-
way. Under basal conditions, FAD PS1 mutants are known to
contribute to the endoplasmic reticulum (ER) stress, what in
turn exaggerates Ca2+ release from the ER and leads to in-
creased mitochondrial dysfunctions, as demonstrated in hu-
man FAD brain and lymphocytes, and in FAD murine models
[52–55]. Our study indicates that under acute oxidative stress
evoked by 2dRib, PS1 mutants strongly exacerbate phosphor-
ylation of p53 thus exhibiting gain of function effect over
wtPS1. Moreover, in the presence of mutPS1, p53-
dependent enhancement of p21 protein levels seems to be
associated with retention of p21 in the cytoplasm, where p21
plays anti-apoptotic function. These activities associated with
mutPS1 probably represent a compensatory mechanism
against acute oxidative stress, preventing depolarization of
mitochondrial membrane and apoptosis in FAD cells, and
resulting in higher survival. In SAD cells expressing wtPS1,
this mechanism is absent. As SAD cells like control cells
express wild-type PS1 (wtPS1), the observed higher apoptotic
response in SAD versus control cells most likely reflects the
pathological versus physiological intracellular environment.
Existing data on the cross-talk between PS1 and p53 in an
apoptotic context is only fragmentary. PS1 is an enzymatic
core of a γ-secretase complex which participates in the gen-
eration of Aβ peptides from its precursor AβPP [2, 56]. The
direct mechanistic link between PS1 and p53 was the
Fig. 7 Effect of PFT-α and 2dRib treatment on cell survival.
Lymphocytes from seven SAD patients, seven control subjects and from
FAD patients were incubated for 24 h in the absence or in the presence of
30 mM 2dRib and 30 μMPFT-α. Cell survival was assessed by the MTT
assay. Results represent the percent of cell survival of treated cells referred
to untreated ones. Data shown are the means ± SEM for at least three
independent experiments carried out for each cell line. Statistically sig-
nificant differences (two-way ANOVA test with Tukey post-test) are
marked **p < 0.01; *p < 0.05
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demonstration that APP-derived amyloid intracellular C-
terminal domain (AICD) fragments generated by γ-secretase
can function as transcription factors activating p53 transcrip-
tion, and that some PS1 mutants augment this process,
resulting in higher levels of the p53 protein [57, 58].
Moreover, upregulated p53 levels were shown to be associat-
ed with a decreased proteasome activity in cells with mutated
PS1 [59]. Consistently with low APP expression levels in B
cells [60], p53 transcriptional regulation was not detected in
our study in FAD cells; neither was lower degradation.
Instead, this is the first documentation of the link between
PS1 mutants and the activation of p53 by phosphorylation at
Ser15, resulting in the upregulation of p21 levels. Moreover,
this is the first description of the association of PS1 mutants
with the mechanisms responsible for cytoplasmic p21 locali-
zation, known to determine anti-apoptotic cellular response.
At present, we can only speculate about the molecular
mechanisms involved in the effects of PS1 mutations control-
ling the cellular response to 2dRib, and several hypothesis can
be formed. In addition to APP, there are over 90 γ-secretase
substrates including Notch, and γ-secretase-dependent effects
on apoptosis are currently explored [61]. Moreover, PS1 plays
a number of γ-secretase-independent functions in processes
associated with cell fate and apoptosis regulation, such as
Wnt/β-catenin signaling, mitochondrial proapoptotic PS1-
associated protein (PSAP) signaling, and calcium homeostasis
(reviewed in [62]). Further studies are required for identifica-
tion of signaling pathways leading from mutPS1 to p53
phosphorylation.
Mutations in PS1 have been associated with an increase in
the vulnerability of neurons to several damaging factors [63,
64] in contrast to the apoptosis resistance detected in lympho-
cytes from FAD patients. However, contradictory data show-
ing lower apoptosis in neurons bearing mutPS1 also exists
(reviewed in [35]). In this regard, it is worth highlighting that
FAD mutations in PS1 were shown to have distinct features
depending on the location in the PS1 structure, especially
differing location in the PS1 first cytoplasmic loop and trans-
membrane regions [65–67]. To minimize this source of vari-
ability, in this study, all investigated mutations were located
outside the first loop, and six of them in the transmembrane
regions (Table 2). Importantly, our previous report marked the
differences in p21 content and cell cycle regulation between
SAD and FAD lymphocytes bearing the same PS1 mutations
as analyzed here [10]. It appears, therefore, that in FAD cells,
there is a precise modulation of the total levels of p21 both in
basal conditions [10] and upon oxidative stress (this manu-
script), leading to G1/S progression and increasing the total
cellular and cytoplasmic p21 protein content, and an increased
resistance to 2dRib-induced apoptosis.
Neuronal cell cycle dysfunctions that lead to apoptosis are
believed to contribute to AD pathogenesis [11, 68, 69].
Nevertheless, one has to take into account that although the
dysfunctions of cell cycle control in the brain and in lympho-
cytes may have similar causes, the mitogenic stimulation to
enter the cell cycle has different consequences. Lymphocytes
from FAD patients show a shorter G1 phase and an increased
resistance to 2dRib-induced cell death than cells derived from
non-demented individuals or SAD patients. These features
might represent an adaptive response for FAD cells that are
exposed to accumulating oxidative challenges and degenera-
tive processes during disease progression. It has been consid-
ered that susceptible neurons in AD survive for a long time in
a compromised way by delaying the apoptotic process, a
mechanism termed abortive apoptosis [70]. However, cell cy-
cle re-activation in already adult neurons results in cellular
dysfunction, premature cell death, and thus neurodegeneration
[8, 12, 71].
Although the observations made in FAD lymphocytes may
not exactly reflect the changes occurring in FAD brains, the
fact that p21 levels change in response to both mitogenic
stimuli and cellular stressors, may offer an explanation for
the relationship between cellular stress and unscheduled cell
cycle entry observed in susceptible AD neurons in agreement
with the Btwo-hit^ hypothesis [12, 72, 73].
In summary, we have detected important differences be-
tween B lymphocytes from SAD and FAD patients when it
comes to the mechanisms involved in regulation of p53 activ-
ity, cellular p21 levels and cell fate in response to an oxidative
challenge. FAD PS1 mutations proved to be associated with
the p53-mediated increase in p21 transcription and cytoplas-
mic localization, resulting in a survival advantage against
2dRib-induced apoptosis. This compensatory mechanism is
absent in SAD cells bearing wtPS1. Thus, caution should be
taken in extrapolating data obtained from cellular or animal
models based in FAD mutations, as they may not be relevant
in SAD. Consistently, therapeutic designs should take into
account the possible effect variability in SAD versus FAD
cells. Particularly, the possible differential responses of FAD
versus SAD B-lymphocytes are important for active vaccina-
tion strategies in AD. This data is also relevant for the recently
developing area of studies concerning the role of systemic
immune cells in AD pathogenesis and for the development
of new blood-based diagnostic methodologies targeting pro-
teins and genes in lymphocytes.
Materials and Methods
Subjects
Demographics and genetic characteristics of all subjects en-
rolled in this study are provided in Tables 1 and 2. All indi-
viduals were enrolled in the Department of Neurology at the
Central Clinical Hospital (MSWiA) in Warsaw, Poland, or in
the Hospital Doce de Octubre in Madrid, Spain. A clinical
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diagnosis of probable AD was performed according to the
criteria of the Diagnostic and Statistical Manual of Mental
Disorders, 4th edition (DSM-IV) and the criteria of the
National Institute on Aging and Alzheimer’s Association
workgroups [74]. All subjects were examined by a neurologist
and a neuropsychologist. The diagnosis was based on an in-
terview, an objective and neurological examination, a cogni-
tive evaluation, and laboratory and radiological tests; a com-
puter tomography scan with an assessment of hippocampal
fissure was obtained for each patient. The laboratory tests
diagnosing FAD included screening of PS1 gene either using
RT-PCR method or genomic DNA analysis, as described ear-
lier [75, 76]. The cognitive status was quantified using the
Mini-Mental State Examination (MMSE). Seven subjects
were diagnosed as FAD, each with at least one first-degree
relative who had suffered from early onset, AD-type demen-
tia, and with a mutation in the PS1 gene. All control subjects
were non-demented, with no clinical signs of neurological or
psychiatric diseases, and normal cognitive and neuropsycho-
logical test results. The average education level of the control
and AD groups was not different, and the proportions of fe-
male to male subjects were even. All study protocols were
approved both by the Ethics Committee for Studies on
Human Subjects at the MSWiA Hospital in Warsaw (agree-
ment nos. 89/2014, 102/2010), Poland, and by the Spanish
Council of Higher Research Institutional Review Board, and
are in compliance with the National and European Union leg-
islation, and the Code of Ethical Principles for Medical
Research Involving Human Subjects of the World Medical
Association. Peripheral blood samples were collected from
all subjects after obtaining written informed consent from
the patients or their representatives. None of the subjects
was affected with neoplastic or autoimmune diseases when
the blood samples were taken.
Cell Lines
Peripheral blood lymphocytes were separated from heparin-
ized blood by centrifugation on Ficoll-Hypaque (Sigma-
Aldrich, St. Louis, MO, USA). Cells were washed twice with
phosphate buffered saline (PBS), counted, and resuspended at
the desired concentration. Immortalized B-lymphocytes were
established with the Epstein–Barr virus using the standard
procedure as described in [10]. Cells were grown in suspen-
sion in T flasks in an upright position, in approximately 10mL
RPMI-1640 medium that contained 2 mM L-glutamine,
100 mg/mL penicillin/streptomycin, and 10 % (v/v) fetal bo-
vine serum, and were maintained in a humidified 5 % CO2
incubator at 37 °C. All reagents needed for cell culture were
purchased in Sigma-Aldrich. Fluid was routinely changed ev-
ery 2 days by removing the medium above the settled cells and
replacing it with an equal volume of fresh medium.
Preparation of Whole-Cell Extracts and Subcellular
Fractionation
To prepare whole-cell extracts, cells were harvested, washed
in PBS, and then lysed in an ice-cold buffer (50 mMTris
pH 7.4, 150 mM NaCl, 50 mM NaF, 1 % Nonidet P-40),
containing 1 mM sodium orthovanadate, 1 mM PMSF,
1 mM sodium pyrophosphate, and protease inhibitor
Complete Mini Mixture (Roche). To separate the cytosolic
and nuclear fractions, cells were harvested, washed in PBS,
and then lysed in an ice-cold hypotonic buffer (10 mM
HEPES, pH 7.9, 10 mM KCl, 0.1 mM ethylenediaminetetra-
acetic acid (EDTA), 0.1 mM ethylene glycol tetraacetic acid
(EGTA), 1 mM sodium orthovanadate, 1 mM sodium pyro-
phosphate, 1 mM PMSF, and protease inhibitor mixture).
After extraction on ice for 15 min, 0.5 % Nonidet P-40 was
added and the lysed cells were centrifuged at 4,000 rpm for
10 min. Supernatants containing cytosolic proteins were sep-
arated, and nuclei were washed twice with the hypotonic buff-
er, and then lysed in a hypertonic buffer (20 mM HEPES,
pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM
sodium orthovanadate, 1 mM sodium pyrophosphate, 1 mM
PMSF, and protease inhibitor mixture). After extraction on ice
for 30 min, the samples were centrifuged at 15,000 rpm for
15 min at 4 °C. Antibodies to α-tubulin and to lamin B were
used to assess the purity of the fractions. The protein content
of the extracts was determined by the Pierce BCA Protein
Assay kit (Thermo Scientific, Waltham, MA, USA).
Table 2 Characteristic of FAD subjects in the Polish population
Mutation in PS1 and its localizationa MMSE ApoE
PS1 M139 V, TDa II 7 E3/E3
PS1 L153 V, TD II 18 E3/E3
PS1 H163R, TD III 11 E3/E3
PS1 S170F, TD III 11 E3/E3
PS1 F177 L, TD III 21 E3/E3
PS1 I213F, TD IV 0 E3/E4
PS1 E318G, L II 26 E3/E3
a Localization of FAD mutations in the PS1 structure is based on nine
transmembrane PS1 model [78]
TD transmembrane domain, L loop
Table 1 Characteristics of the study subjects
Subjects Mean age of onset MMSE
FAD (7 patients) 38.1 ± 7.3 13.4 ± 8.5
F-CTR (12 middle-aged subjects) 38.5 ± 9.6 ≥25
SAD (17 patients) 68.6 ± 9.8 14.4 ± 7.3
S-CTR (17 elderly subjects) 72.2 ± 5.9 27.9 ± 1.0
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Immunoblotting
Samples were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), and trans-
ferred to poly(vinylidene) fluoride (PVDF) membrane
(Immobilon-P, Bio-Rad Laboratories, Richmond, CA, USA).
Equal amounts of protein (20–50 μg) were loaded in each
lane. Uniformity of sample loading and the integrity of trans-
fer were verified by staining with Ponceau-S (Sigma-Aldrich).
After transfer, the PVDF membranes were blocked with non-
fat milk and incubated overnight at 4 °C with primary anti-
bodies, followed by secondary antibodies conjugated to horse-
radish peroxidase (HRP). Detection of the immunoreaction
was performed with an enhanced chemiluminescence (ECL)
kit (Amersham BioSciences, Amersham, UK). Protein band
densities were quantified using Image J software (NIH,
Bethesda, MD, USA) after scanning the images with a GS-
800 densitometer from Bio-Rad.
Antibodies
Anti-p21 rabbit monoclonal antibody (1:1,000), rabbit poly-
clonal anti-p53 antibody (1:1,000), and phospho-p53 (ser15)
(1:1,000) were purchased from Cell Signaling (Danvers, MA,
USA). Mouse monoclonal antibodies: anti-β-actin (1:1,000),
anti-α-tubulin (1:1,000), and anti-Lamin B (1:1,000) were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA).
Quantitative Real-Time PCR
Lymphocytes from controls, as well as SAD and FAD individ-
uals were seeded at an initial density of 1 × 106 cells × mL−1 in
RPMI and incubated for 24 h with or without 30 mM 2-deoxy-
D-ribose. After stimulation, cells were collected and total RNA
was extracted from cell cultures using Trizol™ reagent
(Invitrogen, Waltham, MA, USA). RNA yields were quantified
spectrophotometrically and RNA quality was checked by the
A260/A280 ratio and on a 1.2 % agarose gel to observe the
integrity of 18S and 28S rRNA. RNA was then treated with
DNase I Amplification Grade (Invitrogen). One microgram
was reverse transcribed with the Superscript III Reverse
Transcriptase kit (Invitrogen). Quantitative real-time PCR was
performed in triplicates using TaqMan™ Universal PCR
MasterMix No Amperase UNG (Applied Biosystems,
Carlsbad, CA, USA) reagent according to the manufacturer’s
protocol. Primers were designed using the Universal Probe
Library for Human (Roche Applied Science, Roche, Penzberg,
Bavaria, Germany) and used at a final concentration of 20 μM.
The sequences of the forward and reverse primers used are as
follows: for p21, 5′-cgaagtcagttccttgtggag-3′ and 5′-
catgggttctgacggacat-3′; and for β-actin, 5′-ccaaccgcgagaagatga-
3′ and 5′-ccagaggcgtacagggatag-3. Real-time quantitative PCR
was performed in the Bio-Rad iQ5 system using a thermal pro-
file of an initial 5-min melting step at 95 °C, followed by 40 cy-
cles at 95 °C for 10 s and 60 °C for 60 s. Relative mRNA levels
of the genes of interest were normalized to β-actin expression
using the simplified comparative threshold cycle delta CT meth-
od [2−(ΔCT gene of interest −ΔCT β-actin].
Trypan Blue Staining
Cell suspension was mixed with 0.4 % (w/v) Trypan Blue
solution (Sigma-Aldrich), and the number of live cells was
determined using a hemocytometer. Cells that failed to ex-
clude the dye were considered nonviable.
MTTAssay
This assay is based on the ability of viable cells to reduce
yellow MTT to blue formazan. Cells were seeded at an initial
concentration of 1 × 106 cells × mL−1 on 96-well plates. After
24 h of treatment with 30 mM 2-deoxy-D-ribose and/or α-
pifithrin cells were incubated with 20 μl of MTT (thiazolyl
blue tetrazolium bromide (1 mg/mL, 3 h) and subsequently
solubilized in dimethyl sulfoxide (DMSO). The extent of re-
duction ofMTTwas quantified by absorbancemeasurement at
595 nm with 630 nm as a reference wavelength, according to
the manufacturer’s protocol. Cell survival was estimated as
the percentage of the value of untreated controls. All reagents
were purchased from Sigma-Aldrich.
Confocal Laser Scanning Microscopy
Cells were fixed for 15min in 4% paraformaldehyde, washed in
PBS/BSA, and cytospun at 700 rpm for 7 min onto poly-L-
lysine-coated slides. Then they were blocked and permeabilized
with 0.5 % Triton X-100 in PBS-0.5 %BSA for 20 min at room
temperature and incubated with rabbit anti-p21 antibody
(1:500). After washing with PBS, cells were incubated with
Alexa Fluor 488-conjugated anti-rabbit antibody. The prepara-
tions were mounted on ProLong® Gold Antifade Reagent with
DAPI (Thermo Fisher) and visualized with LEICA TCS-SP5-
AOBS confocal microscope system (Heidelberg, Germany).
Flow Cytometry Cell Cycle Analysis
Distribution of cells in SubG1, S, and G2/M cell cycle phases
was measured based on propidium iodide (PI) staining using
standard flow cytometry method. Cell lines were seeded at an
initial concentration of 1 × 106 cells mL−1 and incubated for
24 h with or without 30 mM 2-deoxy-D-ribose. Exponentially
growing cells were used in a single cell cycle measurement
performed in triplicate with fluorescence-activated cell sorting
(FACS). After centrifugation (400×g, 4 °C, 5 min), cells were
washed with PBS, suspended in 70 % cold ethanol for 1 h,
Mol Neurobiol
washed again and incubated for 1 h in 0.1 % sodium citrate in
PBS containing RNase (10 μg/mL) and 50 μg/mL PI (Sigma-
Aldrich). Measurements were performed using FACSCalibur
instrument (Becton Dickinson, Franklin Lakes, NJ, USA).
Prior to analysis, cells were equilibrated to room temperature.
Exactly 10,000 events from each sample were collected in a
single cell gate. Aggregates and debris were excluded from
analysis by creating the gate on the FL2-W (transit time) ver-
sus FL2-A (total cell fluorescence) cytogram according to the
standard procedure [77]. The percentages of cells in SubG1
phase were determined based on the frequency distribution of
DNA content with ModFit LT software (version 3.1, Verity
Software House, Topsham, Maine).
Annexin VAssay
Apoptosis was measured by flow cytometry using Annexin V-
FITC (Sigma-Aldrich) and propidium iodide (Sigma-Aldrich)
staining. Cell lines were seeded at an initial concentration of
1 × 106 cells mL−1. After 24 h cells were collected, centrifuged
(400×g, 4 °C, 5min) andwashedwith 1ml PBS.Afterward cells
were incubated 15 min in the dark and on ice in 100 μl Annexin
V incubation buffer (0.1 M Hepes, 25 mM CaCl2, 1.4 M NaCl)
with 1 μl Annexin V-FITC. After incubation 400 μl Annexin
binding buffer with 2 μl PI (50 μg/ml) were added. By staining
cells with a combination of Annexin V-FITC and PI, it is possi-
ble to distinguish and quantitatively analyze non-apoptotic cells
(Annexin V-FITC negative/PI negative), early apoptotic cells
(Annexin V-FITC positive/PI negative), late apoptotic/necrotic
cells (Annexin V-FITC positive/PI positive), and dead cells
(Annexin V-FITC negative/PI positive). Measurements were
performed using FACSCalibur instrument (Becton Dickinson)
and data were analyzed with BD Cell Quest Pro Software.
Mitochondrial Membrane Potential (MMP) Assessment
To assess MMP, staining with cationic dye JC-1 was performed.
Cells were seeded at a density of 1 × 106 cells mL−1 and treated
with or without 30 mM 2-deoxy-D-ribose. After 24 h cells were
collected, centrifuged (400×g, 4 °C, 5 min) and washed twice
with PBS. After washing, cells were incubated for 20 min in the
incubator (37 °C, 5%CO2) with 10 μl JC-1 staining solution
(MitoProbe Jc-1 Assay Kit, Invitrogen) diluted in 1 ml PBS.
Healthy cells with functional mitochondria containing red JC-1
aggregates are detectable in FL-2 channel. Apoptotic or un-
healthy cells with collapsed mitochondria contain mainly green
JC-1 monomers and are detectable in FL-1 channel. As a posi-
tive control we used carbonyl cyanide m-chlorophenyl
hydrazone (CCCP), which is a chemical inhibitor of oxidative
phosphorylation and causes an uncoupling of the proton gradi-
ent. Measurements were performed using FACSCalibur instru-
ment (Becton Dickinson). Analysis was made with BD Cell
Quest Pro Software.
Statistics
Statistical analyses were performed with Graph Pad Prism 6 (La
Jolla, CA, USA). All the statistical data are presented as
mean ± standard error of the mean (SEM). Normality was
checked with the Shapiro–Wilk test. Parametric tests were there-
fore used in the statistical analysis. Based on the expertise
achieved on previous works we can expect that, with the sample
size we used and the significance level we fixed, the variability
within groups will be low enough and the differences between
groups to detect will be high enough to ensure a statistical power
above 0.9. Statistical significancewas estimated by the Student’s
t test or, when appropriated, by one-way and two-way analysis
of variance (ANOVA) followed by the Tukey’s test for multiple
comparisons. A value of p < 0.05 was considered significant.
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